NEW YORK, January 12, 2021 – EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based off of an ab initio designed antibody.
EVQLV’s 100 sample validation run was designed to validate the company’s claim that they could ab initio design an antibody by computer (without prior templates) that would hit a target epitope. This time around, EVQLV wants to know, given an antibody that binds to a target epitope, how many lead-ready antibodies they can generate that hit the target within a predefined affinity range. EVQLV’s goal is to create a large range of antibodies with limited developability risks and binding affinities. EVQLV’s laboratory collaborator will use their proprietary technology to compile the one million submitted sequences into a sub-library.
Results are expected by Q3 2021.